Antibody-mediated immunity against tuberculosis: implications for vaccine development
about
Tuberculosis vaccines and prevention of infectionB in TB: B Cells as Mediators of Clinically Relevant Immune Responses in TuberculosisBoosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosisField Science--the Nature and Utility of Scientific FieldsLatently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis.The human antibody response to the surface of Mycobacterium tuberculosis.A rational framework for evaluating the next generation of vaccines against Mycobacterium avium subspecies paratuberculosis.Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosisAdvancing host-directed therapy for tuberculosis.The role of B cells and humoral immunity in Mycobacterium tuberculosis infectionUnderstanding and overcoming the barriers to T cell-mediated immunity against tuberculosisReflections on the immunology of tuberculosis: will we ever unravel the skein?Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset.Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful TreatmentT7 Phage Display Library a Promising Strategy to Detect Tuberculosis Specific Biomarkers.Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine EfficacyImmunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.B cells and antibodies in the defense against Mycobacterium tuberculosis infectionEnhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine.Antibody response against PhoP efficiently discriminates among healthy individuals, tuberculosis patients and their contacts.Single Nucleotide Polymorphisms in P2X7 Gene Are Associated with Serum Immunoglobulin G Responses to Mycobacterium tuberculosis in Tuberculosis Patients.Immunogenicity of mycobacterial vesicles in humans: identification of a new tuberculosis antibody biomarker.Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction.Vaccination sequence effects on immunological response and tissue bacterial burden in paratuberculosis infection in a rabbit model.A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.Sequence diversity in the pe_pgrs genes of Mycobacterium tuberculosis is independent of human T cell recognitionM2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection.Exploration of novel cellular and serological antigen biomarkers in the ORFeome of Mycobacterium tuberculosis.Comparative analysis of Bacillus subtilis spores and monophosphoryl lipid A as adjuvants of protein-based mycobacterium tuberculosis-based vaccines: partial requirement for interleukin-17a for induction of protective immunity.The current state of tuberculosis vaccinesHost-directed therapeutics for tuberculosis: can we harness the host?An overview of tuberculosis plant-derived vaccines.Mycobacterium tuberculosis virulence: insights and impact on vaccine development.Humanized NOG mice as a model for tuberculosis vaccine-induced immunity: a comparative analysis with the mouse and guinea pig models of tuberculosis.Shared characteristics between Mycobacterium tuberculosis and fungi contribute to virulence.Novel and recurrent AID mutations underlie prevalent autosomal recessive form of HIGM in consanguineous patients.Evaluation of PE_PGRS33 as a potential surface target for humoral responses against Mycobacterium tuberculosis.Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis."The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.
P2860
Q26782022-572980DF-A427-447D-8109-1FC40656B05FQ26786655-D7B78A47-E436-4C6C-93F6-E50615B418EBQ27315911-3CDC3A7F-D9BC-47C4-AAE3-85FDD4E88AE2Q28606570-CEB239A0-E2BF-451F-BD0C-29AE6AE68E53Q33719289-C2C06E97-45E0-458D-91C2-9DF95741BFE7Q33740190-3FAE74E4-C9D7-4012-8708-7A570DB2EAEAQ34154197-DDB0324F-9BE4-46D0-A6EB-38155D0CEA54Q34334767-4767D503-DA1B-4F20-B207-1CFB9265EA1AQ34466861-EBD2C96C-56C1-47CD-AB94-D126B66C7B1CQ35039807-D4742D88-E850-4F56-8331-7177A36C2BB0Q35039934-40113638-6D86-45D7-B871-3A67B70E1009Q35101417-35C935AF-8CB5-4079-B3BF-3B6BB9530BFDQ35164284-7A55A3A4-3C62-4E8B-BF48-A233AE0C1CB3Q35214233-183DA840-32D7-4DF8-9F4A-EEEBEDD81176Q36052946-ED845946-5D7D-436B-8A99-9EA6D7842C62Q36199050-78A347BB-E0FE-4A04-8840-9F33BF7292BDQ36219941-5EF5A8B5-57C7-4FF0-A651-102FC389F121Q36229621-94A952AE-1139-4411-A3BA-BFAC77354BE9Q36238031-D1C9A131-E399-4181-88D8-D84CC206BFF0Q36302781-4FC97043-2D8D-44E7-861E-B7684D94891DQ36314805-189D36A9-2CF3-4814-A770-75AEA52178D2Q36423946-23A37218-A3A3-4673-950A-152E580E149DQ36927153-AD4EEA44-15E7-4512-836B-7A1B25DAC161Q37033066-B8A92DF7-4EF5-4D27-8838-540AF1B8BAEAQ37156509-B82ACF87-450F-4DF9-AAF4-44037D2B0690Q37204894-320E8A73-3F77-45FC-B1C8-D5F234CD237BQ37519858-DC3A49E8-5754-4E8C-856E-93ABC2370CAEQ37609295-AA03C37E-CE20-42ED-B9C8-DF40F311FE11Q37623652-689E069A-5059-4945-AA7C-471E1AD2A9A1Q37712810-07A2749C-6B7A-4F51-A2AE-6E7976307D36Q38116351-C9982CA8-BED9-4152-87F8-53B993578607Q38168037-4C08367B-23CC-4E28-9B1A-70DC0A7C8841Q38356275-40421273-CE56-4603-8E0C-57E7BEEEC082Q38539493-692D09C2-72CA-4CF7-ADE0-673F2FFC49C2Q38787325-F951DB8F-2AFC-4DCF-93EB-B1DFAAFB40A8Q39171375-B2CD4B3F-9E2F-4A9B-B16C-B8ADA34D4827Q39330315-31FE526C-0CB1-4323-AFC5-BF8F87CEFCF7Q40045707-CAA2B838-66BA-4D44-9DCC-DA5128312847Q40170246-94D6CFD8-5667-4C96-A27E-8747E541945EQ40213126-ECECF5E5-1B11-4815-A735-35C8E558D70D
P2860
Antibody-mediated immunity against tuberculosis: implications for vaccine development
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antibody-mediated immunity against tuberculosis: implications for vaccine development
@en
Antibody-mediated immunity against tuberculosis: implications for vaccine development.
@nl
type
label
Antibody-mediated immunity against tuberculosis: implications for vaccine development
@en
Antibody-mediated immunity against tuberculosis: implications for vaccine development.
@nl
prefLabel
Antibody-mediated immunity against tuberculosis: implications for vaccine development
@en
Antibody-mediated immunity against tuberculosis: implications for vaccine development.
@nl
P2860
P1433
P1476
Antibody-mediated immunity against tuberculosis: implications for vaccine development
@en
P2093
Jacqueline M Achkar
P2860
P304
P356
10.1016/J.CHOM.2013.02.009
P577
2013-03-01T00:00:00Z